List of Excipients in Branded Drug VIDEX

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bristol-Myers Squibb Company	VIDEX EC	didanosine	0087-6671	CARBOXYMETHYLCELLULOSE SODIUM
Bristol-Myers Squibb Company	VIDEX EC	didanosine	0087-6671	DIETHYL PHTHALATE
Bristol-Myers Squibb Company	VIDEX EC	didanosine	0087-6671	GELATIN
Bristol-Myers Squibb Company	VIDEX EC	didanosine	0087-6671	METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER
Bristol-Myers Squibb Company	VIDEX EC	didanosine	0087-6671	SODIUM HYDROXIDE
Bristol-Myers Squibb Company	VIDEX EC	didanosine	0087-6671	SODIUM STARCH GLYCOLATE TYPE A POTATO

VIDEX (Didanosine) Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

VIDEX, the brand name for didanosine, is an obsolete nucleoside reverse transcriptase inhibitor with limited current commercial value in the United States. Its excipient strategy was driven by didanosine’s acid sensitivity, poor palatability, pediatric dosing needs, and food-related absorption constraints. The main commercial opportunities now are generic supply in selected international markets, pediatric or fixed-dose reformulation, and specialized manufacturing of buffered or enteric-coated dosage forms. U.S. market entry faces weak demand because modern antiretroviral regimens have replaced didanosine and the reference product is no longer a meaningful commercial benchmark.

What is VIDEX and what dosage forms were commercialized?

VIDEX contains didanosine, also known as ddI, an antiretroviral nucleoside analog. Bristol-Myers Squibb commercialized several formulations:

Formulation	Core technical purpose	Historical commercial role
Buffered chewable/dispersible tablets	Protect didanosine from gastric acidity and permit administration after dispersion	Original adult and pediatric formulation
Pediatric powder for oral solution	Flexible weight-based dosing	Pediatric and swallowing-limited patients
VIDEX EC delayed-release capsules	Protect didanosine from gastric acid without requiring a large buffer load	Later formulation intended to improve convenience and reduce tablet burden

The FDA-approved indications covered HIV-1 infection, generally in combination with other antiretroviral agents. Current U.S. HIV treatment guidelines no longer recommend didanosine as a routine component of initial or maintenance therapy because of toxicity, pharmacokinetic limitations, and the availability of safer agents.[1]

What excipient strategy protected didanosine stability and absorption?

Didanosine is acid-labile. Its formulation must reduce contact with gastric acid or otherwise maintain a sufficiently high microenvironmental pH. This technical requirement determined the historical VIDEX excipient platform.

Buffered tablets and oral powder

The original VIDEX dosage forms used an alkaline buffering system. Calcium carbonate and magnesium hydroxide were central to the buffering approach in the chewable/dispersible tablet presentation. The buffer raised local pH and reduced acid-mediated degradation after administration.[2]

The dosage form also needed excipients for:

• Tablet compression and mechanical strength
• Rapid dispersion in water
• Taste masking
• Powder flow
• Suspension stability
• Palatability in children
• Dose uniformity at low pediatric doses

Historically disclosed excipient classes included sweeteners, flavoring agents, binders, disintegrants, lubricants, and alkaline mineral buffers. Exact inactive-ingredient composition differed by presentation and market. Regulatory labeling should control any product-development decision because commercial formulations and strengths were not necessarily identical across jurisdictions.[2,3]

VIDEX EC enteric-coated capsules

VIDEX EC used enteric-coated beadlets inside a hard gelatin capsule. The objective was to delay release until the dosage form passed through the stomach. This allowed the product to reduce reliance on the high buffer load used in the original chewable tablets.[3]

The formulation architecture typically involved:

1. Didanosine-containing multiparticulates or beadlets.
2. A seal or protective coating.
3. An enteric polymer layer.
4. Encapsulation in a hard gelatin shell.

This design shifted the product’s technical risk from buffer capacity to coating performance. Critical quality attributes included:

• Acid resistance during gastric transit
• Release at intestinal pH
• Coating uniformity
• Beadlet size distribution
• Didanosine assay and content uniformity
• Dissolution profile
• Moisture control
• Stability under long-term storage

Enteric-coated multiparticulates can support more consistent protection than a simple alkaline tablet, but they require specialized coating equipment, process controls, and dissolution testing.

What formulations are protected by the VIDEX excipient platform?

The commercial value of VIDEX formulation technology was concentrated in three technical categories.

Buffered oral solid formulations

Buffered tablets and powders protect didanosine through pH modification. The main intellectual-property targets are:

• Specific ratios of didanosine to alkaline buffer
• Tablet compositions with defined dissolution characteristics
• Dispersible tablets with improved taste or stability
• Pediatric powders that maintain dose uniformity after reconstitution
• Storage-stable formulations with low moisture uptake

These claims can be difficult to enforce where a generic manufacturer uses a different buffer system or a non-infringing acid-protection mechanism.

Enteric-coated beadlets

The EC formulation creates a stronger manufacturing barrier than a conventional tablet because it requires multiparticulate coating and performance testing. Relevant claim categories include:

• Didanosine-containing beadlets
• Specific polymer coating layers
• Coating weight gain
• Acid-stage dissolution limits
• Intestinal-stage release
• Capsule compositions
• Manufacturing sequences for applying the coating

The commercial barrier is more likely to arise from process capability and bioequivalence risk than from surviving U.S. patent exclusivity.

Pediatric liquid or dispersible products

Pediatric formulations require separate development work because didanosine has an unpleasant taste and historically required acid protection. Commercial opportunities include:

• Low-dose dispersible tablets
• Ready-to-use suspensions
• Unit-dose sachets
• Flavor-masked powders
• Age-appropriate dosing devices
• Heat- and humidity-stable presentations for low-resource markets

Pediatric products may have greater differentiation potential than adult capsules, but demand is constrained by the decline in didanosine use.

When did VIDEX lose exclusivity?

Didanosine is an old small-molecule active ingredient. Its original compound and early formulation exclusivity periods expired years ago. No U.S. biologic exclusivity applies because didanosine is not a biologic.

Exclusivity category	VIDEX position
New chemical entity exclusivity	Expired
Original compound patent protection	Expired
Pediatric exclusivity	Historical, if granted for specific FDA requirements; expired
Orphan exclusivity	Not the principal commercial protection
Biosimilar exclusivity	Not applicable
Current branded formulation exclusivity	No meaningful active U.S. exclusivity identified in current commercial practice

The exact U.S. patent estate must be confirmed against historical Orange Book editions, assignment records, and terminal-disclaimer data. The practical market conclusion is clear: current entry risk is regulatory and commercial rather than dependent on a live compound patent.

What is the Orange Book status of VIDEX?

VIDEX and VIDEX EC were historically listed in the FDA Orange Book under Bristol-Myers Squibb-related sponsorship. The products are no longer significant U.S. commercial products, and discontinued-product status affects the relevance of historical listings.[4]

An Orange Book entry does not by itself establish current market opportunity. A potential applicant must distinguish among:

• Active reference products
• Discontinued reference products
• Withdrawn applications
• Historical patents
• Patent listings that have expired
• Products for which FDA considers an abbreviated new drug application pathway available

For a generic applicant, the important regulatory issue is whether FDA will accept the proposed product as therapeutically equivalent to a listed reference product or require another pathway because the reference presentation is no longer marketed or lacks a current comparator.

Are Paragraph IV challenges still relevant for VIDEX?

Paragraph IV litigation is unlikely to be a current commercial constraint for didanosine because the core patent estate is historical. Paragraph IV certifications were more relevant during the original generic-entry period, particularly for delayed-release or other formulation-specific products.

A current applicant would evaluate:

• Whether any listed patent remains unexpired
• Whether the listed reference product has a qualifying active status
• Whether a formulation patent has already expired
• Whether a non-infringement or invalidity certification is required
• Whether FDA will accept an ANDA referencing the relevant dosage form
• Whether an NDA or 505(b)(2) pathway is more practical

The absence of active litigation does not guarantee approval. Bioequivalence against an old or unavailable reference product can create a larger operational issue than patent certification.

What generic entry risks exist for VIDEX?

The major risks are commercial erosion, bioequivalence complexity, and limited clinical demand.

Regulatory and technical risks

A generic manufacturer may face difficulty reproducing the performance of the EC multiparticulate system. Key risks include:

• Failure to match acid-stage protection
• Early release of didanosine in the stomach
• Delayed or incomplete intestinal release
• Inconsistent beadlet coating
• Food-effect differences
• Inadequate stability under high humidity
• Taste or dispersion failures in pediatric products

For buffered tablets, the central risk is not only active-ingredient assay. It is the interaction among buffer capacity, tablet disintegration, gastric exposure, and absorption.

Commercial risks

Modern agents such as tenofovir alafenamide, dolutegravir, bictegravir, and boosted protease-inhibitor combinations have displaced didanosine in most treatment settings. Didanosine has been associated with clinically important toxicities, including pancreatitis, peripheral neuropathy, mitochondrial toxicity, and lipoatrophy. Those concerns restrict use even when the product is technically available.[1,5]

The result is a market in which low manufacturing cost does not necessarily produce attractive returns. Procurement tenders, public-sector demand, and country-specific treatment guidelines will determine viable volume.

Which companies are challenging or competing with VIDEX?

No major branded company is currently positioning didanosine as a growth product. Competition comes from generic manufacturers and from replacement antiretroviral products rather than from another didanosine brand.

Competitive group	Competitive effect
Generic didanosine manufacturers	Price competition in remaining markets
Tenofovir-based products	Preferred replacement for older nucleoside analogs
Integrase-inhibitor regimens	Reduced clinical demand for didanosine-containing combinations
Fixed-dose combination manufacturers	Simplified dosing and stronger adherence profile
Local public-sector suppliers	Regional tender competition

The commercial substitute is not another didanosine formulation. It is a modern antiretroviral regimen with better tolerability, simpler dosing, and stronger guideline support.

What licensing deals and manufacturing opportunities exist?

There is no current high-value licensing market around the VIDEX brand comparable to active oncology, immunology, or specialty biologic assets. Opportunities are more likely to involve technical transfer, regional registration, or contract manufacturing.

Potential transaction structures include:

• Acquisition of dormant didanosine registrations
• Regional commercialization rights
• Technology transfer for enteric-coated beadlets
• Contract manufacture of buffered oral solids
• Supply agreements for pediatric powders
• Portfolio licensing bundled with other legacy HIV products
• Government or nongovernmental procurement contracts

The highest-value asset would not be the VIDEX trademark. It would be a validated formulation and regulatory package that allows low-cost production in markets where didanosine remains listed in treatment protocols.

How strong is the VIDEX patent estate?

The current U.S. patent estate is weak as a commercial barrier because the relevant product history dates to the early antiretroviral era and core patent terms have expired. The formulation technology may still have know-how value even where patent rights no longer block entry.

Patent-estate factor	Assessment
Compound protection	Expired
Basic formulation protection	Primarily expired
Enteric-coating know-how	Technically relevant, but not necessarily patent-blocking
Manufacturing trade secrets	Potential value in process control and coating parameters
U.S. litigation risk	Low based on the product’s current commercial status
International patent risk	Country-specific and generally limited by age of the asset
Freedom-to-operate risk	More dependent on current excipient and process patents than on VIDEX patents

An applicant must screen current patents on enteric polymers, coating processes, multiparticulate systems, and capsule manufacture. Those patents would likely be third-party platform patents rather than VIDEX-specific rights.

What is the FDA regulatory status of didanosine?

Didanosine received FDA approval for HIV treatment before current antiretroviral standards were established. The product’s clinical role declined as newer agents became available. FDA labeling remains a historical reference for dosage, warnings, drug interactions, and formulation requirements, but labeling availability should not be confused with active commercial demand.[2,3]

A company seeking to commercialize didanosine today would need to assess whether the relevant reference product remains suitable for an ANDA, whether a 505(b)(2) application is required, and whether a new formulation would need additional clinical or pharmacokinetic support.

What revenue exposure does VIDEX create for Bristol-Myers Squibb?

VIDEX no longer represents a material revenue driver for Bristol-Myers Squibb. The product’s commercial importance ended after HIV treatment shifted toward newer agents and combination products.

Revenue exposure for a potential generic entrant is also limited:

• Unit prices are likely to be low.
• Treatment volumes are declining.
• Public tenders can compress margins.
• Registration costs may exceed expected sales in many countries.
• Pediatric or specialty formulations may command better pricing but serve smaller populations.
• Manufacturing complexity is highest for the EC capsule, while demand is weakest for the legacy product.

The strongest business case would require an existing HIV portfolio, established regulatory infrastructure, and access to markets where didanosine remains included in procurement programs.

What generic launch scenarios are commercially realistic?

Scenario 1: Low-cost buffered tablet

This is the simplest manufacturing opportunity. It requires established tablet production, alkaline buffering, and appropriate taste and dispersion performance. The product could compete in low-income markets if treatment protocols still permit didanosine.

Scenario 2: Enteric-coated capsule

This product has greater technical differentiation but higher development and manufacturing costs. It may be attractive only where a clear reference product and sufficient tender volume exist.

Scenario 3: Pediatric dispersible formulation

A pediatric product could address dosing and administration problems that remain relevant in resource-constrained settings. The opportunity depends on current pediatric HIV guidelines and procurement demand.

Scenario 4: Reformulated didanosine combination

A fixed-dose combination could improve adherence, but the clinical and regulatory case is weak because didanosine itself is no longer a preferred component of most modern regimens.

How does VIDEX compare with modern antiretroviral products?

Attribute	VIDEX	Modern integrase-based therapy
Dosing convenience	Historically difficult, including food and formulation restrictions	Usually once daily
Toxicity profile	Higher concern for mitochondrial, pancreatic, and neuropathic effects	Generally more favorable
Formulation complexity	Buffering or enteric protection required	Typically conventional oral solid dosage forms
Guideline position	Legacy or limited use	Preferred in most treatment settings
Patent value	Mostly expired	Active or recently expired estates may remain
Commercial demand	Narrow and declining	Broad and commercially significant
Biosimilar relevance	None	None for small-molecule products; biologic analogies do not apply

Key Takeaways

• VIDEX is didanosine, an older HIV nucleoside analog with limited current commercial relevance.
• Its excipient strategy centered on acid protection through alkaline buffering or enteric-coated multiparticulates.
• Calcium carbonate and magnesium hydroxide were important historical buffer components in the chewable/dispersible tablet platform.
• VIDEX EC used delayed-release beadlets to protect didanosine from gastric acid.
• Core U.S. compound and formulation exclusivity has expired.
• Current generic risk is primarily commercial and regulatory, not patent-driven.
• Pediatric dispersible products and regional generic supply are the most credible remaining opportunities.
• A new fixed-dose combination containing didanosine has weak commercial logic because modern HIV guidelines favor newer agents.
• Manufacturing know-how for enteric coating may retain value even though the original patent estate is largely exhausted.
• No biosimilar pathway applies because didanosine is a small-molecule drug.

FAQs About VIDEX Excipient Strategy and Commercial Opportunities

Can didanosine be formulated without an alkaline buffer?

Yes, but the formulation must prevent or minimize gastric acid exposure. An enteric-coated multiparticulate or other delayed-release system can replace a conventional high-buffer approach.

Is VIDEX EC easier to manufacture than buffered didanosine tablets?

No. VIDEX EC reduces the buffer burden but requires multiparticulate coating, acid-stage dissolution control, moisture management, and specialized process validation.

Does VIDEX have active U.S. patent protection?

The original didanosine and historical VIDEX protection periods have expired. Current freedom-to-operate analysis still must cover unrelated third-party patents on excipients, enteric polymers, coating processes, and manufacturing equipment.

Is didanosine still used in pediatric HIV treatment?

Its use is limited and generally not preferred where modern antiretroviral alternatives are available. Any pediatric commercial program would depend on country-specific guidelines and procurement practice.[1]

Can a company launch a generic VIDEX product through an ANDA?

Potentially, but the pathway depends on the current reference-product status, dosage form, availability of a suitable comparator, and FDA requirements for demonstrating pharmaceutical equivalence and bioequivalence.

References

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services. https://clinicalinfo.hiv.gov/en/guidelines

2. U.S. Food and Drug Administration. (n.d.). VIDEX (didanosine) prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/

3. National Library of Medicine. (n.d.). Didanosine delayed-release capsules and oral formulations: DailyMed drug labeling. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

5. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Drug characteristics and adverse effects in antiretroviral therapy. U.S. Department of Health and Human Services. https://clinicalinfo.hiv.gov/en/guidelines